Drugs / TYPHIBEV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05500482 | May 2023 → Jan 2026 | typhoid fever | Christian Medical College, Vellore, India | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT07286370 Comparator | Apr 2026 → Apr 2028 expected | salmonellosis | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT07320716 Comparator | Jan 2026 → Oct 2028 expected | diarrheal disease | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06663436 Comparator | Nov 2024 → Oct 2025 | diarrheal disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYPHIBEV | “TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is...” NCT05500482 ↗ |
| Modality | Vaccine | “TyphiBEV®, a typhoid conjugate vaccine from Biological E” NCT05500482 ↗ |
| Route | Intramuscular | “0.5 ml as a single dose given intramuscularly” NCT05500482 ↗ |